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From 1987 to 1994, 16 of 162 cystic fibrosis (CF) patients attending CF clinics at three different hospitals in South 
Wales, U.K. were found to have respiratory secretions colonized with Burkholderia cepacia (B. cepacia). 
Bacteriological typing by polymerase chain reaction (PCR) ribotyping demonstrated seven strains of B. cepacia 
among these 16 CF patients. This typing confirmed that cross-infection was the mechanism of colonization in six 
of the nine patients who were colonized at the paediatric CF clinic at the University Hospital of Wales in 
Cardiff, and in three of the six patients who were colonized at the adult CF clinic at Llandough Hospital in Cardiff 
(cross-infection rate nine of 16 patients or 56%). 
A search was made for a nosocomial source, with screening of yrards and clinics. Swabs from fomites produced 
four positive cultures for B. cepacia. Two isolates had the same PCR ribotype as that of the previous CF room 
occupant. 
To establish prevalence of B. cepacia among CF children living throughout Wales, respiratory secretions were 
cultured from 15 1 of 186 CF children (age < 16 years). This failed to demonstrate B. cepacia colonization other than 
in the CF patients already identified. 
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Introduction 
Burkholderia cepacia (B. cepacia), formerly Pseudomonas 
cepacia, has become an important pathogen among cystic 
fibrosis (CF) patients in recent years (l), and its incidence 
has been rising (2,3). The effects of B. cepacia can be 
different from those produced by Pseudomonas aeruginosa 
(1,4,5); it is of concern that rapid deterioration and death 
has been described in a few CF patients (1,4-7) within a 
short time of colonization. This fulminant course has been 
associated with necrotizing pneumonia and septicaemia 
@,9). 
The mode of transmission of B. cepacia remains contro- 
versial. Evidence has been increasing for person-to-person 
transmission associated with hospital attendance (10,ll) 
and social contact (3,12-14). Nosocomial acquisition of B. 
cepacia has also been suggested (l&16), and acquisition 
from the environment outside the hospital (10). 
Since 1987, within Cardiff, there has been a gradual 
increase in the number of CF patients colonized with 
B. cepacia, both in the paediatric clinic at the University 
Hospital of Wales and the adult clinic at Llandough 
Hospital, which are on opposite sides of the city. 
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Concern over the rising incidence of B. cepacia coloniz- 
ation within the two clinics in Cardiff prompted the authors 
to investigate first, the suspected chain of cross-infection by 
identifying times of contact between patients and typing the 
isolates of B. cepacia. Initial typing involved bacteriocin 
production and sensitivity (Govan JRW, Edinburgh 17,lS) 
and has been reported previously (11); more recent typing 
has been done by the polymerase chain reaction (PCR) 
‘Ribotyping’ method of Kostman et al. (19) modified by 
Ryley et al. (20). Second, in order to establish the preva- 
lence of B. cepacia among paediatric CF patients living in 
Wales, respiratory secretions were screened from as many 
patients as possible. Third, since many of the patients 
appeared to become colonized at the time of hospital 
admission or shortly afterwards, search for a nonsocomial 
source was also commenced. 
Patients and Methods 
PATIENTS 
Sixty-nine CF children (mean age + 1 SD 9.4 f 3.8 years, 33 
female) were studied at the paediatric CF clinic at the 
University Hospital of Wales. An additional 82 CF patients 
(mean age f 1 SD 6.7 f 3.8 years, 39 female) who attended 
other clinics in Wales were studied from March 1992 to 
April 1993 by culture of respiratory secretions. Eighty adult 
CF patients (mean age f 1 SD 23.3 f 4.7 years, 43 female) 
were studied at Llandough Hospital. 
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RESPIRATORY SECRETION COLLECTION 
During the 1Cmonth period from March 1992 until April 
1993, children with CF attending the University Hospital of 
Wales had respiratory secretions collected at outpatient 
visits (usually every 3 months), also on admission to the 
ward and weekly for inpatients. Respiratory secretions were 
similarly collected from adult CF outpatients and inpatients 
attending Llandough Hospital. 
During this same time period, respiratory cultures were 
obtained from 151 of the estimated 186 CF patients in 
Wales (21) who were less than 16 years. Respiratory 
secretions from CF patients outside Cardiff were taken by 
an experienced member of the Cardiff CF team at the time 
of peripheral clinic visits. They were placed either into 
sterile universal containers or obtained as cough swabs 
(produced by asking or stimulating the patient to cough 
onto a swab positioned in the pharynx) and placed in Stuart 
media. To avoid the problems of variation in isolation rates 
for B. cepacia from different laboratories, all specimens 
were brought back to the University Hospital of Wales for 
culture and identification. For specimens obtained at a 
considerable distance from Cardiff, there was an inevitable 
delay in getting specimens to the laboratory (maximum 
transport time, 3 days). 
The authors had demonstrated previously that it was 
possible to isolate B. cepuciu from cough swabs and 
sputum samples kept for up to 4 days, either at room 
temperature or at 4°C. Patients outside Cardiff usually had 
two respiratory secretions tested in this manner over the 
14 months. 
BACTERIOLOGICAL CULTURE AND TYPING 
Secretions were inoculated onto B. cepacia selective media 
containing ticarcillin and polymyxin B (Selectatab Agar, 
Mast Laboratories, Merseyside, U.K.), and incubated aero- 
bically for 48 h at 37°C. Suspect colonies were identified 
using standard bacteriological techniques including the API 
20 NE identification system (Bio Merieux Ltd, Hampshire, 
U.K.). 
Typing of the organism was carried out using a modifi- 
cation of the PCR ‘Ribotyping’ method of Kostman et al. 
(19) as described by Ryley et al. (20). Essentially, PCR 
amplification was done on the intergenic space between the 
16s and 23s rRNA genes on extracted chromosomal DNA 
with the same primers and under similar conditions to those 
described by Kostman et ul. (19). Prior to electrophoretic 
analysis, the PCR products were digested with a restriction 
endonuclease. Taql, resulting in more complex final elec- 
trophoretic patterns which gave greater discrimination 
between types. Pattern differentiation was based on the 
number of bands seen and the relative position and inten- 
sity of staining of each band within the electrophoretic 
pattern. 
ENVIRONMENTAL SCREENING 
From March 1992 over a 12-month period, five single 
occupancy cubicles of known B. cepacia positive patients 
were swabbed in eight designated areas (bed frame, 
mattress, locker, window sill, blind, sink, door handle and 
floor) on the following occasions: after discharge (within 
30 min of the patient vacating the cubicle) before and 
after cleaning the cubicle and, where possible, before 
admission. Immediately following discharge, the atmos- 
phere in the cubicle was tested for 1 min using a slit sampler 
(30 lmin~ ‘). 
Two University Hospital of Wales outpatient clinic 
rooms (used for respiratory function testing and consul- 
tations) were investigated similarly with swabs and a slit 
sampler, on three separate clinic days set aside for patients 
colonized with B. cepaciu. Swabs were taken from the plug 
holes in the sinks, from the finger probe on the pulse 
oximeter, from inside the vitalograph flow head and from 
the grid at the mouth-piece end of the peak flow meter. 
Timing of samples was prior to the clinic visit and immedi- 
ately after each patient had left the room. At the end of the 
clinic, the vitalograph flow-head was dismantled and swabs 
taken from the filters inside. All swabs were moistened 
with polymyxin broth and inoculated immediately into 
B. cepaciu enrichment medium. Incubations, subculture 
and identification were the same as for the respiratory 
secretions. Cultures were obtained, onto B. cepacia selective 
medium, from 193 swabs and 36 slit sampler plates. 
Results 
PAEDIATRIC PATIENTS 
Since 1987, nine CF children (mean age at coloniz- 
ation * 1 SD 11.7 f 2.7 years, five female) attending the 
paediatric clinic at University Hospital of Wales become 
colonized with B. cepacia (Patients A-J, Fig. 1, Table 1). 
Three of the patients died (A-C). PCR typing, prior colo- 
nization with Pseudomonas aeruginosa or Pseudomonas 
species, age at acquisition of B. cepacia, mean duration 
of B. cepacia colonization and age at death are shown in 
Table 1. 
The first patient (A) was identified after a 4-week visit to 
a Canadian holiday camp for people with CF. Burkholderia 
cepacia had never been isolated from this patient’s sputum 
prior to this holiday, despite testing at least 3 monthly over 
the previous 2 years. On the basis of typing, it was 
concluded that a chain of cross-infection derived from this 
index case was responsible for six subsequent cases 
(Patients B-F and J) (Fig. 1). Apart from the index case and 
the siblings, none of the patients had had known contact 
with any other CF patients outside the hospital environ- 
ment. After recognition of the first four cases in 1990, 
management changes were instituted to segregate CF 
patients into single occupancy cubicles while on the ward. 
Children slept and performed physiotherapy in the cubicles, 
but socialized in the school room and play room. Separate 
clinics were established for B. cepacia colonized and 
non-colonized patients. 
Following the failure to contain cross-infection (with 
recognition of Patient F), further management changes 
followed in June 1992 with all paediatric CF patients being 
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FIG. 1. Transmission of Burkholderiu cepacia during hospital admission in cystic fibrosis (CF) patients. The paediatric CF 
patients are A-H and J; the adult patients L-P and R. PCR, polymerase chain reaction. 
partially barrier-nursed. This involved all CF patients being 
nursed in single occupancy cubicles; no socializing was 
allowed in any part of the hospital and social contact 
outside the hospital was discouraged. Each patient had his 
own examination equipment within the cubicle, and strict 
hand washing was performed before and after patients were 
examined. Due to the lack of cubicles with bathroom 
facilities, patients were allowed to use the general ward 
facilities. Despite these efforts to separate patients, Patient J 
became colonized in April 1994 after admission to hospital 
at the same time as Patients C and E. 
PCR ribotyping demonstrated three distinct banding 
patterns with variation in number, position and intensity of 
individual bands. Patients A-F and J all carried PCR type 
1, in keeping with the presumed spread of colonization by 
cross-infection between these patients. Patients G and H, 
however, who had had no known contact with other CF 
patients colonized with B. cepacia, carried ribotyes 2 and 3, 
different from the fore-going and different from each other. 
No patient was colonized more than one type of B. 
cepacia and no changes of type were noted. Once colonized 
with B. cepaciu, all patients, except Patient H, were chroni- 
cally colonized with this organism. Patient H was treated 
with a 2-week course of intravenous antibiotics at the time 
of first isolation of B. cepaciu; following this, the authors 
were unable to re-isolate the bacterium from three sputum 
cultures over 4 months. However, the culture became 
positive again at 5 months, when the PCR ribotype was the 
same as before treatment. 
None of the 82 patients outside Cardiff was colonized 
with B. cepacia, and fewer cultured positive for P. aerugi- 
nova (Table 2). As a group, the CF population outside 
Cardiff was significantly younger than those attending the 
Cardiff clinic (P<O.OOl). Eight months after the close of the 
study, a paediatric patient (Patient K) attending Singleton 
Hospital in Swansea was identified by the local paediatri- 
cian to be colonized with B. cepaciu in December 1993. This 
patient carried yet another PCR ribotype, type 7 (Table 1). 
ADULT PATIENTS 
Since February 1992, six adult patients (mean age at 
colonization f 1 SD 21.1 + 1.9 years, five female) attending 
the CF clinic at Llandough Hospital were found to have 
become colonized with B. cepaciu (Patients L-R, Fig. 1, 
Table 1). Two of these patients died (N and R). PCR 
typing, other microbiological details and age at death are 
shown in Table 1. 
In Llandough hospital, CF patients were not barrier 
nursed in cubicles; however, patients colonized with B. 
cepacia were segregated onto a different ward from those 
not colonized with B. cepacia. Despite being discouraged, 
some patients socialized in other parts of the hospital. 
Bacteriological ribotyping by PCR showed that the iso- 
lates from the paediatric and adult clinics were different, 
and identified three distinct electrophoretic patterns among 
the six patients attending the adult clinic (Table 1). Four of 
these patients (L, M, P and R) who had known contact 
within hospital shared the same type of B. cepacia (PCR 
ribotype 4). Patient N who had had several admissions 
with Patient M and was known to be a close friend, was 
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TABLE 1. Details of patients colonized with Burkholderia cepacia and polymerase chain reaction typing of isolates 
Patient/sex 
PCR Prior 
typing of isolation of Age at Duration of 
Burkholderia Pseudomonas species/ acquisition of Burkholderia cepacia Age at 
cepacia aeruginosa Burkholderia cepacia colonization death 
(l-7) (*I (m-9 (years) (years) 
Paediatric 
A/female 1 + 12.1 3.6 15.7 
B/female 1 + 9.1 3.2 12.3 
C/male 1 + 11.7 4.6 16.3 
D/female 1 + 9.5 4.9 
E/male 1 + 8.5 4.8 
F/male 1 + 9.3 2.9 
G/male 2 + 15.4 2.7 
H/female 3 + 14.3 2.4 
J/female 1 + 15.0 0.9 
K/male 7 5.4 1.3 
Adult 
L/female 4 + 19.8 3.1 
M/female 4 + 18.0 2.9 
N/female 5 + 22.4 0.6 23.0 
O/male 6 + 21.0 2.1 
P/female 4 + 21.2 2.1 
R/female 4 + 23.6 0.8 24.4 
Age (years) Mean * 1 SD 14.8 * 5.7 2.7 f 1.4 18.3 f 5.1 
TABLE 2. Prevalance of Burkholderia cepacia colonization of 
paediatric cystic fibrosis (CF) patients in Wales for the 




Number of CF patients 69 82 
Mean age f 1 SD (years) 9.4 f 3.8 6.7 + 3.8 
Number of respiratory secretions 8 (l-20) 2 (l-11) 
tested per patient median (range) 
Number of patients colonized with: 
Burkholderia cepacia 6 (9%) 0 
Pseudomonas aeruginosa 39 (57%) 18 (22%) 
colonized with a different type of B. cepacia (PCR ribotype 
5). Patient 0, who had no known contact with other 
B. cepacia patients, had the third type of B. cepacia found in 
the adult clinic (PCR ribotype 6). 
ENVIRONMENTAL SCREENING 
Only four positive isolates were found: from a ward cubicle 
floor, from a slit sampler used in a clinic room and from 
each of two sinks in separate clinic rooms. The isolates from 
the cubicle floor and the slit sampler were both PCR 
ribotype 1, the same as that of Patient C who had recently 
occupied the cubicle and clinic room. Samples form the 
sinks were of a different PCR ribotype (not recognized 
among the patients), here termed an ‘environmental strain’. 
Testing of lung function equipment in the paediatric clinic 
failed to culture B. cepacia. 
Discussion 
Burkholderia cepacia has caused widespread concern among 
the CF community for patients and carers alike. Confusion 
over the mode of transmission has caused some of this 
anxiety. Over recent years, there has been increasing 
evidence to support person-to-person transmission of B. 
cepacia between CF patients, both within the hospital 
environment (3,4,11,14,20,22,23) and by social contact out- 
side the hospital (3,12-14). Conversely, other studies have 
not supported person-to-person spread within the CF 
population (5,24-26), suggesting that epidemic spread of 
B. cepacia is not inevitable as not all strains have epidemic 
potential (26). The risk of transmission may be strain 
dependent, and a subgroup of B. cepacia strains has 
been responsible for clustering of cases in particular centres 
(3). In the present study, acquired cross-infection with 
B. cepacia appears to have caused colonization in nine out 
of 16 cases (56%). Six of these patients (all with similar 
ribotype) attended University Hospital of Wales and three 
patients (all with a similar ribotype but different from 
the paediatric cases) attended Llandough Hospital. Trans- 
mission within the home environment appears to have 
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been responsible for two of the cases attending University 
Hospital of Wales (one in each of two families) who were 
siblings of known cases. 
Nosocomial acquisition of B. cepacia by surgical patients 
via cleaning fluids has been well documented (27,28). Evi- 
dence for environmental acquisition has been less certain, 
although contamination has occurred (1,3,10,16,24,29). The 
authors’ search for a nosocomial source at University 
Hospital of Wales produced few positive results despite 
repeat testing; only four positive isolates were obtained, two 
of which were of the same ribotype as the previous room 
occupant, suggesting that nosocomial acquisition may be 
possible. The authors did not obtain positive cultures from 
lung function equipment, like others (l), but these have 
been recorded (1,3,16). 
Controversy surrounds the management of patients 
colonized with B. cepacia. Many centres have introduced 
segregation policies and actively discouraged social contact 
such as attendance at CF meetings and CF holiday camps 
(3,30-32). Such themes have been taken up by the U.K. CF 
Trust which has issued guidelines on restriction of social 
and hospital contact (33) and by the U.S. CF Foundation 
which has ceased to advocate or sponsor summer camps for 
CF patients (34). All this imposes a considerable burden on 
patients and staff alike, and the long-term psychological 
effects are unknown. Segregation of colonized from non- 
colonized patients can create ‘microbiological outcasts’ as 
patients are removed from their usual hospital CF clinic or 
ward, away from friends and familiar hospital staff (32). 
In addition, non-colonized patients become increasingly 
anxious about ‘getting’ B. cepacia (32,35). 
In areas where strict segregation has been used, the 
incidence of B. cepacia colonization of CF patients has 
remained low or has decreased (3 1,36). Segregation policies 
for patients colonized with P. aeruginosa have been operat- 
ing at the Copenhagen CF clinic since 1981 (36); similar 
practices for B. cepacia are thought to have contributed 
to the remaining low incidence of this bacterium at this 
clinic (36,37). At University Hospital of Wales, Cardiff, a 
segregation policy for B. cepacia has been in place since 
1992, following which no further cross-infection occurred 
for 2 years, until Patient J became colonized in 1994. 
Despite counselling, this teenage patient socialized with 
known B. cepacia CF patients who were on the ward at the 
same time. At Llandough Hospital, Cardiff, colonization 
of two further CF patients with B. cepacia followed 
the recognition of the earlier two patients, even although 
efforts were made to separate colonized and non-colonized 
patients onto different wards. 
Five patients in this study (31%) acquired B. cepacia 
having had no known contact with other B. cepacia 
patients. These five patients carried individual ribotypes, 
different from each other and different from the two chains 
of presumed cross-infection recognized at University 
Hospital of Wales and Llandough Hospital. Segregation 
could not have prevented colonization of these patients 
with these particular organisms. 
As in other reports (23,30), the majority of patients in 
this study were colonized with either Pseudomonas species 
or P. aeruginosa, prior to B. cepacia, and there may have 
been a tendency for females to do worse (1,7): 10 of the 16 
patients with B. cepacia were female (among a population 
which was 51% female) as were four of the five deaths. 
Among the 10 paediatric patients colonized, mean age of 
acquisition of B. cepacia (11 .O years & 3.2) was comparable 
with other reports involving paediatric clinics (1,23,38). 
Investigation of 151 of 186 paediatric CF patients 
throughout Wales showed that the prevalence of B. cepacia 
in April 1993 was 4%. At that time, all these six patients 
attended the Cardiff paediatric CF clinic; four were of a 
similar ribotype and colonized by cross-infection. The other 
two were of two further, differing ribotypes and the source of 
their infection is unknown. For these patients, it is possible 
that their older age may have rendered them more liable to 
colonization with B. cepacia. Since isolation of B. cepacia 
from cough swabs kept for up to 4 days was consistently 
possible, the authors are confident that the delay of up to 3 
days for some swabs reaching the laboratory would not have 
affected the detection of this organism from patients attend- 
ing clinics outside Cardiff. However, it is possible that testing 
of fewer respiratory secretions from outside Cardiff may 
have influenced the number of positive findings. 
Person-to-person transmission of B. cepacia between CF 
patients has been the main cause of the rise in incidence of 
colonization of CF patients with this organism in Cardiff. 
Segregation of patients seems to have reduced this trans- 
mission, but sporadic acquisition of B. cepacia has been 
recognized, which would have occurred despite segregation. 
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